Xinyi Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xinyi Zhang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoyan Nie
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; International Research Center for Medicinal Administration, Peking University, Beijing 100191, China
6 shared publications - Christine Y. Lu
The University of Sydney
4 shared publications - Maoyi Tian
School of Public Health, Harbin Medical University, Harbin, China
4 shared publications - Xiaowen Hu
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
4 shared publications - Caiying Wu
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
3 shared publications - Jing Chen
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1800-1814
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study
To evaluate the cost-effectiveness of a one-time mt-sDNA-based colorectal cancer screening program compared with no screening, using real-world data from a government-led population-based screening program in Harbin Municipality of China. This modelling study was based on a real-world mt-sDNA CRC screening program in Chinese primary healthcare settings. The program targeted residents aged 45-64 years without a prior history of CRC. A decision analytic model was developed from the healthcare system perspective to compare mt-sDNA screening with a hypothetical no-screening scenario. Costs included mt-sDNA testing, diagnostic colonoscopy after positive results, adenoma resection, and colorectal cancer treatment by disease stage. Effectiveness was measured in quality-adjusted life-years (QALYs). The primary outcome was the incremental cost-effectiveness ratio (ICER), assessed against a willingness-to-pay threshold of CNY 166,744 per QALY gained. Costs and QALYs were discounted at 5% annually over a lifetime horizon. One-way deterministic sensitivity analysis and probabilistic sensitivity analysis with 10,000 simulations were conducted. Among 749,517 participants, 79,169 had positive mt-sDNA results and 17,364 completed diagnostic colonoscopy, corresponding to a colonoscopy adherence rate of 21.93%. In the base-case analysis, mt-sDNA screening incurred CNY 264 higher lifetime costs and yielded an additional 0.006 QALYs per person versus no screening. The mt-sDNA screening was cost-effective with an ICER of CNY 43,627 per QALY gained. The cost-effectiveness results were particularly sensitive to colonoscopy adherence (ranging from CNY 94,907 to 10,037 per QALY as adherence varied from 10% to 100%) and to the unit cost of the mt-sDNA test (ranging from CNY 22,113 to 65,140 per QALY with a ± 50% variation in cost). All ICERs remained below the cost-effectiveness threshold. The mt-sDNA screening is cost-effective compared to no screening. These findings provide economic evidence to support the large-scale adoption of mt-sDNA-based screening in China.
- 24 June 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1800-1814
Open AccessCost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study
To evaluate the cost-effectiveness of a one-time mt-sDNA-based colorectal cancer screening program compared with no screening, using real-world data from a government-led population-based screening program in Harbin Municipality of China. This modelling study was based on a real-world mt-sDNA CRC screening program in Chinese primary healthcare settings. The program targeted residents aged 45-64 years without a prior history of CRC. A decision analytic model was developed from the healthcare system perspective to compare mt-sDNA screening with a hypothetical no-screening scenario. Costs included mt-sDNA testing, diagnostic colonoscopy after positive results, adenoma resection, and colorectal cancer treatment by disease stage. Effectiveness was measured in quality-adjusted life-years (QALYs). The primary outcome was the incremental cost-effectiveness ratio (ICER), assessed against a willingness-to-pay threshold of CNY 166,744 per QALY gained. Costs and QALYs were discounted at 5% annually over a lifetime horizon. One-way deterministic sensitivity analysis and probabilistic sensitivity analysis with 10,000 simulations were conducted. Among 749,517 participants, 79,169 had positive mt-sDNA results and 17,364 completed diagnostic colonoscopy, corresponding to a colonoscopy adherence rate of 21.93%. In the base-case analysis, mt-sDNA screening incurred CNY 264 higher lifetime costs and yielded an additional 0.006 QALYs per person versus no screening. The mt-sDNA screening was cost-effective with an ICER of CNY 43,627 per QALY gained. The cost-effectiveness results were particularly sensitive to colonoscopy adherence (ranging from CNY 94,907 to 10,037 per QALY as adherence varied from 10% to 100%) and to the unit cost of the mt-sDNA test (ranging from CNY 22,113 to 65,140 per QALY with a ± 50% variation in cost). All ICERs remained below the cost-effectiveness threshold. The mt-sDNA screening is cost-effective compared to no screening. These findings provide economic evidence to support the large-scale adoption of mt-sDNA-based screening in China.
- Open Access
- 25 August 2025
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 11, e72978
Dietary Risk Factors and Associated Disease Burden Among Chinese Adults Aged 25 Years and Older: Systematic Analysis of the Global Burden of Disease Study 2021
Background: With rapid economic development and lifestyle changes, diet-related diseases have become a major public health concern globally. China is experiencing significant dietary transitions. From 2001 to 2021, the intake of staple foods declined, while the consumption of animal-based foods and ultraprocessed foods increased significantly. But comprehensive assessments of major dietary risk factors and the long-term health impacts of shifting dietary patterns in China remain unclear. Objective: This study aims to assess the disease burden attributable to dietary risk factors in China using data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021), and to examine long-term trends over the past 3 decades. In addition, it provides an in-depth analysis of the 3 major diet-related disease categories in China: cardiovascular diseases, neoplasms, and diabetes and kidney diseases. Methods: We extracted data from GBD 2021, focusing on diet-related health outcomes in China across 33 provinces and regions. Measures included deaths, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs), stratified by age, sex, and region. Age-standardized rates (ASRs) were calculated, and temporal trends were analyzed using estimated annual percentage change (EAPC). Results: In 2021, dietary risk factors accounted for 1.70 million deaths and 38.39 million DALYs among Chinese adults aged 25 years and older. The leading contributors were high sodium intake, low fruit consumption, and low whole grain intake. Cardiovascular diseases were the largest contributors to diet-related DALYs. The burden was more pronounced in males than in females and highest among older adults aged 80 years and older. Substantial regional variation was observed, with the Northeastern and Western regions showing higher burden. From 1990 to 2021, overall disease burden due to dietary risks declined steadily, as reflected by decreasing ASR-DALYs (EAPC= -1.76), YLLs, and death rates. In contrast, YLDs showed a slight upward trend (EAPC=0.75), indicating a shift toward increased years lived with disability. In addition, the relative contributions of specific dietary risk factors changed considerably. Low vegetable intake, once ranked the third in 1990, dropped to the 12 th by 2021, while high red meat consumption rose from the 15 th to 7 th place. Although the ranking of high-sugar beverage consumption did not change, the ASR-DALYs rate increased significantly, with a percentage change of 689.14% between 1990 and 2021. Conclusions: In China, the burden of diet-related diseases remains substantial. While the overall age-standardized disease burden has declined, marked regional and demographic disparities persist. Certain dietary risks, such as high red meat and sugar-sweetened beverage consumption, are rising, and high sodium intake remains a serious concern. These trends highlight the urgent need for comprehensive, adaptable, and evidence-based nutrition policies to be implemented to address the evolving diet-related disease burden across diverse populations in China.
- 25 August 2025
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 11, e72978
Open AccessDietary Risk Factors and Associated Disease Burden Among Chinese Adults Aged 25 Years and Older: Systematic Analysis of the Global Burden of Disease Study 2021
Background: With rapid economic development and lifestyle changes, diet-related diseases have become a major public health concern globally. China is experiencing significant dietary transitions. From 2001 to 2021, the intake of staple foods declined, while the consumption of animal-based foods and ultraprocessed foods increased significantly. But comprehensive assessments of major dietary risk factors and the long-term health impacts of shifting dietary patterns in China remain unclear. Objective: This study aims to assess the disease burden attributable to dietary risk factors in China using data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021), and to examine long-term trends over the past 3 decades. In addition, it provides an in-depth analysis of the 3 major diet-related disease categories in China: cardiovascular diseases, neoplasms, and diabetes and kidney diseases. Methods: We extracted data from GBD 2021, focusing on diet-related health outcomes in China across 33 provinces and regions. Measures included deaths, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs), stratified by age, sex, and region. Age-standardized rates (ASRs) were calculated, and temporal trends were analyzed using estimated annual percentage change (EAPC). Results: In 2021, dietary risk factors accounted for 1.70 million deaths and 38.39 million DALYs among Chinese adults aged 25 years and older. The leading contributors were high sodium intake, low fruit consumption, and low whole grain intake. Cardiovascular diseases were the largest contributors to diet-related DALYs. The burden was more pronounced in males than in females and highest among older adults aged 80 years and older. Substantial regional variation was observed, with the Northeastern and Western regions showing higher burden. From 1990 to 2021, overall disease burden due to dietary risks declined steadily, as reflected by decreasing ASR-DALYs (EAPC= -1.76), YLLs, and death rates. In contrast, YLDs showed a slight upward trend (EAPC=0.75), indicating a shift toward increased years lived with disability. In addition, the relative contributions of specific dietary risk factors changed considerably. Low vegetable intake, once ranked the third in 1990, dropped to the 12 th by 2021, while high red meat consumption rose from the 15 th to 7 th place. Although the ranking of high-sugar beverage consumption did not change, the ASR-DALYs rate increased significantly, with a percentage change of 689.14% between 1990 and 2021. Conclusions: In China, the burden of diet-related diseases remains substantial. While the overall age-standardized disease burden has declined, marked regional and demographic disparities persist. Certain dietary risks, such as high red meat and sugar-sweetened beverage consumption, are rising, and high sodium intake remains a serious concern. These trends highlight the urgent need for comprehensive, adaptable, and evidence-based nutrition policies to be implemented to address the evolving diet-related disease burden across diverse populations in China.
- Open Access
- 26 December 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 54, 101272
Using primary and routinely collected data to determine prevalence and patterns of multimorbidity in rural China: a representative cross-sectional study of 6474 Chinese adults
- 26 December 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 54, 101272
Open AccessUsing primary and routinely collected data to determine prevalence and patterns of multimorbidity in rural China: a representative cross-sectional study of 6474 Chinese adults
- 1 May 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (5) , 1031-1040
Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes
BACKGROUND: The SSaSS (Salt Substitute and Stroke Study) has shown that use of a potassium-enriched salt lowers the risk of stroke, total cardiovascular events, and premature death. The effects on cause-specific cardiac outcomes are reported here. METHODS: SSaSS was an unblinded, cluster-randomised trial assessing the effects of potassium-enriched salt compared with regular salt among 20 995 Chinese adults with established stroke and older age and uncontrolled hypertension. Post hoc efficacy analyses were performed using an intention-to-treat method and a hierarchical Poisson regression model adjusting for clustering to obtain rate ratios and 95% CIs. We assessed acute coronary syndrome, heart failure, arrhythmia, and sudden death. RESULTS: Over a mean 4.74 years follow-up, there were 695 acute coronary syndrome events, 454 heart failure events, 230 arrhythmia events, and 1133 sudden deaths recorded. The rates of events were lower in potassium-enriched salt group for all outcomes but CIs were wide for most: acute coronary syndrome (6.32 versus 7.65 events per 1000 person-years; rate ratio, 0.80 [95% CI, 0.65–0.99]); heart failure (9.14 versus 11.32 events per 1000 person-years; rate ratio, 0.88 [95% CI, 0.60–1.28]); arrhythmia (4.43 versus 6.20 events per 1000 person-years; rate ratio, 0.59 [95% CI, 0.35–0.98]); and sudden death (11.01 versus 11.76 events per 1000 person-years; rate ratio, 0.94 [95% CI, 0.82–1.07]; all P >0.05 with adjustment for multiple comparisons). CONCLUSIONS: These results suggest that use of potassium-enriched salt is more likely to prevent than cause cardiac disease but the post hoc nature of these analyses precludes definitive conclusions. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02092090.
- 1 May 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (5) , 1031-1040
Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes
BACKGROUND: The SSaSS (Salt Substitute and Stroke Study) has shown that use of a potassium-enriched salt lowers the risk of stroke, total cardiovascular events, and premature death. The effects on cause-specific cardiac outcomes are reported here. METHODS: SSaSS was an unblinded, cluster-randomised trial assessing the effects of potassium-enriched salt compared with regular salt among 20 995 Chinese adults with established stroke and older age and uncontrolled hypertension. Post hoc efficacy analyses were performed using an intention-to-treat method and a hierarchical Poisson regression model adjusting for clustering to obtain rate ratios and 95% CIs. We assessed acute coronary syndrome, heart failure, arrhythmia, and sudden death. RESULTS: Over a mean 4.74 years follow-up, there were 695 acute coronary syndrome events, 454 heart failure events, 230 arrhythmia events, and 1133 sudden deaths recorded. The rates of events were lower in potassium-enriched salt group for all outcomes but CIs were wide for most: acute coronary syndrome (6.32 versus 7.65 events per 1000 person-years; rate ratio, 0.80 [95% CI, 0.65–0.99]); heart failure (9.14 versus 11.32 events per 1000 person-years; rate ratio, 0.88 [95% CI, 0.60–1.28]); arrhythmia (4.43 versus 6.20 events per 1000 person-years; rate ratio, 0.59 [95% CI, 0.35–0.98]); and sudden death (11.01 versus 11.76 events per 1000 person-years; rate ratio, 0.94 [95% CI, 0.82–1.07]; all P >0.05 with adjustment for multiple comparisons). CONCLUSIONS: These results suggest that use of potassium-enriched salt is more likely to prevent than cause cardiac disease but the post hoc nature of these analyses precludes definitive conclusions. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02092090.
- Open Access
- 30 October 2023
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 180, 105273
Features, functions, and quality of mobile applications for type 2 diabetes care in China: Systematic search of app stores
- 30 October 2023
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 180, 105273
Open AccessFeatures, functions, and quality of mobile applications for type 2 diabetes care in China: Systematic search of app stores
- 15 October 2023
- Published by Springer Nature
- p. 638-685
Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases
- 15 October 2023
- Published by Springer Nature
- p. 638-685
Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases
- 24 June 2023
- Published by Springer Nature
- p. 1-49
Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases
- 24 June 2023
- Published by Springer Nature
- p. 1-49
Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases
- Open Access
- 7 December 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (12) , 2021
Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
(1) Background: As prescribers, physicians play a decisive role in applying and promoting pharmacogenomic (PGx) testing in clinical practices. So far, little is known about physicians’ perspectives on PGx testing in China. The aim of this study was to assess physicians’ knowledge of, attitude towards, and experience of PGx testing in China. (2) Methods: A 39-question online survey was developed. Participants were physicians recruited through two platforms, MEDLINKER and “Dazhuanjia”. (3) Results: A total of 450 respondents completed the survey and 366 questionnaires were eligible for analysis based on the inclusion criteria. Among all included physicians, 275 (75.1%) had heard of PGx testing before. More than half rated their knowledge of PGx testing as “Fair” (61.5%) while 20.0% chose “Excellent” or “Good” and 18.6% chose “Poor” or “Terrible”. “Guidelines, consensus, and treatment paths for disease diagnosis and treatment” (72.7%) were the most preferred sources of information about PGx testing. Respondents were confident in their personal capacity to conduct PGx, with an average score of 3.30 ± 0.09 (out of 5.00). Most respondents (75.6%) believed that PGx could “help to improve efficacy and reduce the incidence of adverse reactions”. Targeted cancer therapy (score 78.95 ± 1.26 out of 100) was considered the field where PGx testing had its highest value. Lack of professionals and knowledge (n = 186, 67.6%), high costs of testing (n = 170, 61.8%), and lack of hospitals to offer PGx testing (n = 166, 60.4%) were identified as the primary obstacles to increasing the uptake of PGx testing in China. Academic conference (n = 213, 72.4%) was considered the most efficient way for physicians to obtain information about PGx testing. (4) Conclusions: Physicians in China have poor knowledge about PGx testing; nonetheless, they generally had confidence in their capacity to order PGx testing and positive attitudes towards the use of PGx testing in routine clinical practices. Future efforts to promote the uptake of PGx testing should focus on foundational education and practical training.
- 7 December 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (12) , 2021
Open AccessPhysicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
(1) Background: As prescribers, physicians play a decisive role in applying and promoting pharmacogenomic (PGx) testing in clinical practices. So far, little is known about physicians’ perspectives on PGx testing in China. The aim of this study was to assess physicians’ knowledge of, attitude towards, and experience of PGx testing in China. (2) Methods: A 39-question online survey was developed. Participants were physicians recruited through two platforms, MEDLINKER and “Dazhuanjia”. (3) Results: A total of 450 respondents completed the survey and 366 questionnaires were eligible for analysis based on the inclusion criteria. Among all included physicians, 275 (75.1%) had heard of PGx testing before. More than half rated their knowledge of PGx testing as “Fair” (61.5%) while 20.0% chose “Excellent” or “Good” and 18.6% chose “Poor” or “Terrible”. “Guidelines, consensus, and treatment paths for disease diagnosis and treatment” (72.7%) were the most preferred sources of information about PGx testing. Respondents were confident in their personal capacity to conduct PGx, with an average score of 3.30 ± 0.09 (out of 5.00). Most respondents (75.6%) believed that PGx could “help to improve efficacy and reduce the incidence of adverse reactions”. Targeted cancer therapy (score 78.95 ± 1.26 out of 100) was considered the field where PGx testing had its highest value. Lack of professionals and knowledge (n = 186, 67.6%), high costs of testing (n = 170, 61.8%), and lack of hospitals to offer PGx testing (n = 166, 60.4%) were identified as the primary obstacles to increasing the uptake of PGx testing in China. Academic conference (n = 213, 72.4%) was considered the most efficient way for physicians to obtain information about PGx testing. (4) Conclusions: Physicians in China have poor knowledge about PGx testing; nonetheless, they generally had confidence in their capacity to order PGx testing and positive attitudes towards the use of PGx testing in routine clinical practices. Future efforts to promote the uptake of PGx testing should focus on foundational education and practical training.
- Open Access
- 21 August 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (8) , 1348
Clinical Pharmacists’ Knowledge of and Attitudes toward Pharmacogenomic Testing in China
(1) Background: Uptake of pharmacogenomic testing in routine clinical practices is currently slow in China. Pharmacists might play an important role in leveraging care through applying pharmacogenomics, therefore, it is important to better understand clinical pharmacists’ knowledge of and attitudes toward pharmacogenomic testing, which has not been well-studied. (2) Methods: A self-administered survey was developed based on previous knowledge of pharmacogenomic testing and its uptake in China. Participants were recruited through the Committee of Pharmaceutical Affairs Management under the Chinese Hospital Association. (3) Results: A total of 1005 clinical pharmacists completed the questionnaire, among whom 996 (99.10%) had heard of pharmacogenomic testing before participation. More than half of respondents (60.0%, n = 597) rated their knowledge of pharmacogenomic testing as “average”, while 25% rated it “good” or “excellent”. “Guidelines, consensus and treatment paths for disease diagnosis and treatment” (78.7%) were the most preferred sources of information about pharmacogenomic testing. Most respondents (77.0%) believed that pharmacogenomics could “help to improve efficacy and reduce the incidence of adverse reactions”. Our participants also believed that patients would benefit most from pharmacogenomic testing through better prediction of individual drug responses and thus informed treatment decisions. The top challenge for the uptake of pharmacogenomic testing was its high cost or lack of insurance coverage (76.7%). (4) Conclusions: Most Chinese clinical pharmacists who participated in our study had a positive attitude toward pharmacogenomic testing, while the knowledge of pharmacogenomic testing was generally self-assessed as average.
- 21 August 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (8) , 1348
Open AccessClinical Pharmacists’ Knowledge of and Attitudes toward Pharmacogenomic Testing in China
(1) Background: Uptake of pharmacogenomic testing in routine clinical practices is currently slow in China. Pharmacists might play an important role in leveraging care through applying pharmacogenomics, therefore, it is important to better understand clinical pharmacists’ knowledge of and attitudes toward pharmacogenomic testing, which has not been well-studied. (2) Methods: A self-administered survey was developed based on previous knowledge of pharmacogenomic testing and its uptake in China. Participants were recruited through the Committee of Pharmaceutical Affairs Management under the Chinese Hospital Association. (3) Results: A total of 1005 clinical pharmacists completed the questionnaire, among whom 996 (99.10%) had heard of pharmacogenomic testing before participation. More than half of respondents (60.0%, n = 597) rated their knowledge of pharmacogenomic testing as “average”, while 25% rated it “good” or “excellent”. “Guidelines, consensus and treatment paths for disease diagnosis and treatment” (78.7%) were the most preferred sources of information about pharmacogenomic testing. Most respondents (77.0%) believed that pharmacogenomics could “help to improve efficacy and reduce the incidence of adverse reactions”. Our participants also believed that patients would benefit most from pharmacogenomic testing through better prediction of individual drug responses and thus informed treatment decisions. The top challenge for the uptake of pharmacogenomic testing was its high cost or lack of insurance coverage (76.7%). (4) Conclusions: Most Chinese clinical pharmacists who participated in our study had a positive attitude toward pharmacogenomic testing, while the knowledge of pharmacogenomic testing was generally self-assessed as average.
- Open Access
- 31 July 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (8) , 1267
Clinical Pharmacists’ Involvement in Pharmacogenomics Testing and Related Services in China
Background: Pharmacogenomics (PGx) testing is increasingly used in clinical practice to optimize drug therapies. This study aims to understand the involvement of clinical pharmacists in PGx testing at tertiary hospitals in China and their self-assessed capacity to deliver such services. Methods: We developed a questionnaire exploring clinical pharmacists’ involvement and self-assessed level of capacity of performing PGx tests. A random sample was obtained from the Pharmaceutical Affairs Management Professional Committee of the Chinese Hospital Association. Results: A total of 1005 clinical pharmacists completed the survey. Of these, 996 (99.1%) had heard of PGx tests and 588 (59.0%) had been involved in PGx testing and related services. Some clinical pharmacists (28.9%) provided PGx services at the rate of “1–5 cases/year” while 21.9% of clinical pharmacists provided PGx services at the rate of “>30 cases/year”. Clinical pharmacists most frequently provided PGx testing for cardiovascular diseases. “Consult relevant guidelines/literature” (90.1%) was the most frequently used method to familiarize oneself with PGx testing. About 60% of the pharmacists considered themselves to have poor or fair capacity to provide PGx testing and related services. Conclusions: More than half of the pharmacists had been involved in PGx testing and related services. However, pharmacists generally had little confidence in their knowledge level of and capacity to provide PGx-related services.
- 31 July 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (8) , 1267
Open AccessClinical Pharmacists’ Involvement in Pharmacogenomics Testing and Related Services in China
Background: Pharmacogenomics (PGx) testing is increasingly used in clinical practice to optimize drug therapies. This study aims to understand the involvement of clinical pharmacists in PGx testing at tertiary hospitals in China and their self-assessed capacity to deliver such services. Methods: We developed a questionnaire exploring clinical pharmacists’ involvement and self-assessed level of capacity of performing PGx tests. A random sample was obtained from the Pharmaceutical Affairs Management Professional Committee of the Chinese Hospital Association. Results: A total of 1005 clinical pharmacists completed the survey. Of these, 996 (99.1%) had heard of PGx tests and 588 (59.0%) had been involved in PGx testing and related services. Some clinical pharmacists (28.9%) provided PGx services at the rate of “1–5 cases/year” while 21.9% of clinical pharmacists provided PGx services at the rate of “>30 cases/year”. Clinical pharmacists most frequently provided PGx testing for cardiovascular diseases. “Consult relevant guidelines/literature” (90.1%) was the most frequently used method to familiarize oneself with PGx testing. About 60% of the pharmacists considered themselves to have poor or fair capacity to provide PGx testing and related services. Conclusions: More than half of the pharmacists had been involved in PGx testing and related services. However, pharmacists generally had little confidence in their knowledge level of and capacity to provide PGx-related services.